Related Experiment Videos

Aspirin versus anticoagulation in intra- and extracranial vertebral artery dissection

A Arauz1, A Ruiz, G Pacheco

  • 1Stroke Clinic, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, México City (DF), México. antonio.arauz@prodigy.net.mx

Insights

Recurrent ischaemic stroke is rare in patients with vertebral artery dissection (VAD) treated with aspirin or oral anticoagulation. The choice of antithrombotic therapy did not significantly impact outcomes or bleeding complications.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Cardiology

Background:

  • Vertebral artery dissection (VAD) is a significant cause of stroke in younger adults.
  • Antithrombotic therapy is standard, but optimal choice between aspirin and oral anticoagulation (OA) remains debated.
  • Understanding recurrent event rates and adverse events is crucial for patient management.

Purpose of the Study:

  • To determine the incidence and predictors of recurrent ischaemic stroke after a first VAD.
  • To evaluate adverse events associated with aspirin versus OA in VAD patients.
  • To assess the impact of antithrombotic choice on functional outcomes.

Main Methods:

  • Retrospective analysis of a 21-year database of 110 patients with confirmed VAD (first-ever ischaemic stroke).
  • Patients were treated with either aspirin or oral anticoagulation (OA).
  • Outcomes included recurrent ischaemic events and major bleeding; functional outcome assessed using modified Rankin score.

Main Results:

  • Recurrent ischaemic events were rare (one case) during follow-up.
  • No significant difference in baseline characteristics or outcomes between aspirin and OA groups.
  • No bleeding complications were reported; good functional outcome (mRS ≤ 2) in 82 patients.

Conclusions:

  • The frequency of recurrent ischaemic stroke in VAD patients appears low.
  • Antithrombotic treatment choice (aspirin vs. OA) did not influence outcomes or bleeding risk in this cohort.
  • Further non-randomized studies support the safety and efficacy of both aspirin and OA for VAD management.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...